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1. Introduction 
The health-care sector is amongst the largest sectors worldwide. In many developed countries, 
annual spending on health care exceeds 10% of GDP, totaling a global spending amount of more 
than 7 trillion USD in 2015. In addition to the current size, the Economist Intelligence Unit 
forecasts future growth rates for health care above GDP and population growth.1 Companies 
included in the health-care sector comprise activities related to the supply of health care services, 
supply of technology and equipment as well as pharmaceuticals, biotechnology, and medical 
research. Each industry had different dynamics. Investments in this sector are affected by many 
variables, including positive trends related to demographics. 
There are many assumptions and expectations with regards to health care investments. First, 
the business grows due to demographics. Second, as health care spending increases with rising 
wealth, growth should be driven by emerging markets. Third, the high labor insensitivity business 
models are expected to decline, whereas technology driven business models are on the rise. 
Fourth, generic drugs are replacing new drugs with high development costs. Fifth, patients are 
dependent on medicine even in economically bad times and therefore investments are particularly 
crisis proof compared to other investments. The goal of this article is a broad overview on 
investments in the health-care sector from several perspectives, addressing the above-mentioned 
assumptions and expectations.  
The literature on health care is generally very extensive. Naturally, there is a huge body of 
literature in the field of natural sciences and medicine, as well as in the field of combining business 
and medicine. However, literature covering the financial performance of health-care investments 
is scant. To the best of our knowledge, there is only one study that covers the performance of 
                                                 
1 For more details see http://www.eiu.com/industry/Healthcare. 
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health care investments in detail (Trsel et al. (2014)). Moreover, few studies focus on very special 
topics in health care performance (e.g., Bredthauer et. al. (2015)), and several studies include 
health care among several branches in their samples (e.g., Fama and French (1997), Hong et al. 
(2007)).  
Trsel et al. (2014), the only study focusing solely on health care, examines the sector from an 
US view in a long term empirical analysis from 1926 to 2009. According to their data, health care 
stocks have generated economically significant risk-adjusted returns in the region of 1.8% to 
3.5%, annually. In addition, health care investments have provided a lower correlation with the 
market. For a 25-year period ending December 2009, health care stocks had a correlation of 0.7 
with the broad market, lower than that of any of the other industries the authors examine. 
Bredthauer et al. (2015) investigate the performance of the US health care industry with a special 
focus on the presidential administration’s political party and the Federal Reserve’s monetary 
policy. In their 60-year time period from 1954 to 2013, Bredthauer et al. (2015) find significantly 
positive alphas. The health care industry experienced positive abnormal returns during 
contractionary monetary regimes and when a Republican was president during expansionary 
monetary regimes. After 1985, Democratic administrations and contractionary monetary regimes 
have coincided with positive health care returns, as have Republican administrations and 
expansionary monetary regimes. Guirguis et al. (2001) analyze 223 health care IPOs during 1985 
and 1996. They find a statistically significant outperformance to the market, but no statistically 
abnormal returns for IPOs relative to matched control firms.  
As mentioned above, there are several studies covering multiple branches, also including 
health care investments in their samples. The most famous example is Fama and French (1997). 
Using the capital asset pricing model and the Fama and French three factor model, the authors 
analyze 48 industries, of which three are related to health care in a period from June 1968 to 1994. 
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In both models, the three portfolios show positive alphas, but only pharmaceutical products and 
medical equipment show a significant outperformance in the three factor model. Hong et. al. 
(2007) present various industry portfolios. The international (non US) health-care portfolio 
exhhibits a positive mean return of almost 1% per month over a period from 1973 to 2002. Dellva 
et al. (2001) analyze Fidelity Sector Mutual Funds from 1989 to 1998. In their sample, the Fidelity 
Select Health Care mutual fund can also be found. They conclude that the health care fund was 
one of the funds that outperformed the S&P 500.  
The literature analysis demonstrates a gap in research. The existing studies indicate that there 
is an outperformance of the health-care sector. However, further details are missing. The aim of 
this article is to close this gap in research. We are the first to study the health-care sector in more 
detail. In particular, we are the first to study a large global sample of more than 3,600 companies. 
We are also the first to compare the industry on a regional basis as well as looking beneath the 
surface and analyzing sub-groups in the health-care sector. In taking into consideration the most 
recent research on performance evaluation (e.g., Nofsinger and Varma (2014)), we are also the 
first to analyze the performance in different market states. Most performance studies are purely 
based on USD returns. In addition to the standard approach, we are the first to shed light on the 
performance of the health-care sector in another currency.  
Our results can be summarized as follows. The health-care sector outperforms the market in a 
period from 2000 to June 2015. The performance is driven by companies from the Americas and 
Asia as well as companies from the pharmaceuticals sub-segment. Bull periods are the main driver 
for the outperformance. Investors that are based in the Euro area can expect divergent outcomes 
with regard to their investments to a USD investor. However, the main trends remain unchanged.  
The next sections are structured as follows: In Section 2 we provide a detailed insight into our 
data, the construction of the portfolios and the methodology used in our analysis. Section 3 
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presents our results, and Section 4 presents some robustness tests: In the last section we present 
various concluding remarks. 
 
2 Data and Methodology 
To investigate the financial performance of the health-care industry around the world, we 
analyze value-weighted portfolios of health-care stocks. The companies are identified by industry 
codes, which is a standard approach in finance (e.g. Fama and French (1997)). As we target a 
global sample, we use the Thomson Reuters business classification codes for our analysis.2 All 
public listed companies, regardless of size, age, origin, etc. which are part of the health-care sector 
(Thomson Reuters sector sectors code 56) are added to our list. We also include all dead 
companies to avoid a survivorship bias. Our total sample consists of 3,680 companies, or, in other 
words, all listed health-care stocks. In addition to the company names, we also collect information 
upon the sub-industries and the origin of each company.  
In order to build our health-care portfolios, we take monthly total return data (including 
dividends) as well as the market capitalization for each company from Thomson Reuters 
Datastream. All data are converted into USD. The valuation is based on the market capitalization 
of the companies at the previous month’s end. Compared with a pure analysis of funds or indices, 
the rather complicated process of building the portfolios gives us the unique opportunity to 
analyze the sample from various perspectives. We form our monthly rebalanced value-weighted 
portfolios for a global, four regional (Americas, Asia, Australia, Europe) and four sub-sector 
samples (biotechnology and medical research, health-care equipment and supplies, health-care 
providers and services, and pharmaceuticals) in the health care industry. As a market benchmark, 
                                                 
2 Previous studies on health care use the SIC (Standard Industrial Classification) codes for their stock selection. As 
our analysis is global, we cannot use a code that is only available for US companies.   
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we use global and regional MSCI Indices. The data is also taken from Datastream. The global and 
regional factors for SMB, HML and WML for the Carhart (1997) four-factor model are extracted 
from Andrea Frazzini’s database. 
Table 1 presents summary statistics for the global health-care portfolio including the 
number of firms, the number of dead firms and the average monthly return for the full-sample 
period from 2000 to June 2015.  
 
(Table 1 about here) 
 
Table 1 already provides some interesting information about the sample. The total sample 
consists of 3,680 companies from all over the world. All companies are combined in a single 
value-weighted portfolio. The positive return of 0.73% per month during the full observation 
period of more than 15 years proves that investors were able to generate a positive outcome of 
their investment in global health-care stocks. 
To provide a first impression of the financial performance of the health-care sector, Figure 
1 illustrates a 100 USD investment in the portfolio of the global health-care sector and the market 
benchmark in the period from January 2000 to June 2015. Within the first eleven years, the health-
care portfolio performs slightly better but, nevertheless, relatively similarly to the market 
benchmark. However, from 2011 onwards, the global health care companies outperform the 
market. At the end, the investment in the market increased to approximately 180 USD, while the 
investment in the health-care portfolio more than tripled, growing to approximately 345 USD. 
These findings indicate that there could be differences between the health-care firms and the 
market in terms of financial performance. 
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(Figure 1 about here) 
 
Time Series Factor Regression Tests 
We use the Carhart (1997) four-factor model to analyze our portfolio. It is an extension of the 
Fama and French (1992, 1993) three-factor model and the capital asset pricing model, which is 
based on Sharpe (1964), Lintner (1965) and Mossin (1966). The four-factor model is widely used 
in financial literature and allows us to compare our results with those of prior studies.  
To take into consideration the latest research on performance evaluation, we study 
different market states (e.g., Nofsinger and Varma (2014)). During the sample period from 
January 2000 to June 2015, we recognize two bear phases in the stock market based on the peak 
and trough of the MSCI World Index. The first bear period covers the period from March 2000 to 
October 2002 and is regarded as the burst of the technology bubble. The second bear period is 
from October 2007 to March 2009 and represents the global financial crisis. These periods for our 
international sample are identical to the bull and bear periods identified by Nofsinger and Varma 
(2014) for the United States and to Lesser et al. (2016) for the global market. 
Our outlined measurement framework translates into the following monthly time-series 
factor regression equation: 
𝑅𝑖 − 𝑅𝑓 = 𝐷𝐵𝑢𝑙𝑙𝑎𝐵𝑢𝑙𝑙 + 𝐷𝐵𝑒𝑎𝑟𝑎𝐵𝑒𝑎𝑟 + 𝑏𝑖𝑀𝐾𝑇 + 𝑠𝑖𝑆𝑀𝐵 + ℎ𝑖𝐻𝑀𝐿 + 𝑤𝑖𝑊𝑀𝐿 + 𝑒𝑖 ,  (1) 
 
The regression describes the Carhart (1997) four-factor model. In the regression, Ri - Rf is 
the monthly excess return of health-care portfolio i and MKT is the monthly excess return of the 
market benchmark and Rf corresponds to the monthly U.S. T-Bill rate. The symbols 𝑎𝐵𝑢𝑙𝑙 and 
𝑎𝐵𝑒𝑎𝑟  represent the alpha estimates measuring out- and underperformance in bull and bear 
periods, respectively, and 𝐷𝐵𝑢𝑙𝑙 (𝐷𝐵𝑒𝑎𝑟) is a dummy variable that takes the value of one during 
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bull (bear) months and zero otherwise, while 𝑒𝑖 is the regression residual. The factors SMB, HML 
and WML are, respectively, the returns on the explanatory factors related to size, value and 
momentum: SMB (small minus big) is the return difference between portfolios of small and big 
stocks in terms of market capitalization, HML (high minus low) is the return difference between 
portfolios of high and low book-to-market stocks and WML (winners minus losers) is the return 
difference between portfolios of stocks with high and low prior twelve-month returns. All factors 
are obtained from Frazzini’s data library.3 The statistical significance of all estimates is derived 
from Newey and West (1987) robust standard errors. Fama and French (2012), as well as Griffin 
(2002), find that size, value and momentum factors are country-specific and that global models 
are not successful in explaining average returns on regional size-value or size-momentum 
portfolios. Therefore, we use global factors only to explain global portfolios, and regional factors 
to explain regional portfolios. 
 
3 Results 
Table 2 presents alpha estimates and characteristics of the portfolio of the health-care 
stocks based on the factor sensitivities relative to the explanatory factors of the Carhart (1997) 
four-factor model over the sample period from 2000 to June 2015.  
 
(Table 2 about here) 
 
Our four-factor model results reveal that the global health-care portfolio outperforms the 
market in the period from 2000 to June 2015. By controlling for size, value and momentum, we 
                                                 
3 Andrea Frazzini’s data library is accessible via http://www.econ.yale.edu/~af227/data_library.htm. 
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find an alpha estimate of 0.36% per month or 4.32% per year, which is significantly different from 
zero. Sample 1 also shows that the health-care stocks are less risky than the market. In addition, 
we observe a negative sensitivity towards the SMB factor, which can be explained through the 
nature of the portfolio. There is a large number of small stocks included in the sample, but due to 
the value weighting of the portfolio, the large caps have a high influence on the total portfolio.  
When considering the regional sample, we observe different results for the four regions. 
While the Americas and Asia both outperform their regional benchmark on a significant basis, 
Australia and Europe do not exhibit alpha estimates that are statistically different from zero. The 
finding for the Americas sample is in line with previous literature (e.g. Trsel et al. (2014)), which 
observes an outperformance of US stocks, which represent the vast majority in our Americas 
sample. Just like the the global sample, the regional health care samples also show betas below 
one. This is reasonable and in accordance with the expectations that are usually combined with 
health care investment.  
Sample 3 reports the results of the industry specific four-factor model regressions. The 
main finding is the outperformance of the pharmaceutical stocks. The three other health-care 
portfolios, being biotechnology & medical research, health care equipment & supplies and health 
care providers & services all have positive alphas, but they are not significantly different to zero. 
To sum up, after controlling for size, value and momentum, we find an outperformance for the 
global portfolio, which appears to be driven by stocks from Americas and Asia as well as by 
stocks from the pharmaceuticals industry. We do not find any negative alphas.  
Previous literature argues that the financial performance may vary during different market 
states (e.g., Nofsinger and Varma (2014)). Thus, we separately investigate bull and bear alpha 
estimates. In particular, stocks of the health-care sector are believed to be more resistant against 
a crisis, as many people depend on medical service and certain drugs and therefore impose a 
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certain degree of demand regardless of the economic situation. Table 3 illustrates the alpha 
estimates during both market conditions, using the performance evaluation model. 
(Table 3 about here) 
 
Moving towards the different market states reveals a different picture to that of the overall 
period. We observe no significant alpha estimates in the bear periods in any of the samples. 
However, we observe significant alphas in bull periods for the global sample as well as for all 
regional and the pharmaceuticals samples. This result is of particular interest as many believe that 
health-care stocks are especially resistant in times of economic downturn and therefore 
outperform the market in bear periods. Our results suggest that the overall health care market 
neither outperforms nor underperforms in bear periods. This could be attributed to the fact that 
large parts of health-care spending is government-related. In phases of economic downturn, 
spending on health care equipment (e.g. in hospitals) is often also reduced and health-insurance 
companies require their customers to use generics instead of highly-priced original drugs. 
However, we find an outperformance for the global portfolio as well as for the regional portfolios 
in bull periods, driven by the pharmaceuticals sample. This could be caused by the fact that during 
economically strong periods, especially in the strongly growing developing markets, more and 
more people can afford health-care services of all kinds and governments are less dependent on 
reducing spending on health care.  
Most academic studies covering the performance of stocks, funds or indices only analyze 
returns based on USD. However, a large set of investors is located outside the US and their 
investment result depends on the outcome in the local currency. Therefore, we additionally 
analyze our portfolios from a European investor’s perspective. The results are presented in Table 
4.  
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(Table 4 about here) 
Our Euro-based four-factor model results reveal that the global health-care portfolio 
outperforms the market in bull periods. This result is statistically significant on the 5% level and 
in line with the USD results shown in the previous tables. For the bear period, we find no 
significant performance difference between the global portfolio and the benchmark, which is also 
consistent to the USD result. For the total period, however, we do not find an outperformance. 
When considering the regional sample we observe different results with respect to the bull periods. 
While we find a trend towards positive outcomes in bull periods for all samples, only the Asian, 
Australian and European portfolios outperform on a significant level. After controlling for size, 
value and momentum, the Americas sample does not outperform on a significant level in the bull 
period anymore. The results for the bear periods are similar to our previous results, as we find no 
alpha estimates that are significantly different to zero. Regarding the total period, only the Asian 
sample outperforms. A look at sample 3 reveals that only the health care equipment and supplies 
industry sub-portfolio outperforms on a 10% level in the bull period. Besides the pharmaceuticals 
portfolio in the bear period, all other portfolios demonstrate an outperformance in the bear period 
and the full period, albeit not a statistically significant one. The results prove that after controlling 
for size, value and momentum, investors can expect different results from their investment if they 
base their investment result on a currency other than USD.  
4 Robustness 
The results of any performance study heavily depend on how the data sample and the 
portfolio are complied as well as the timeframe used. Black (1993) describes such a scenario. To 
avoid any biases, we use the most comprehensive method of building a sample, as we include 
every available company in our sample, even considering now-dead companies. In the previous 
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analysis, we used the market capitalization of each company to construct our portfolio. However, 
there are also other methods used to build a portfolio that can be implemented to test the 
robustness of the results. Academics often apply an equal weighting of the included company 
returns. Even though this approach has the disadvantage that we have to exclude some companies 
such as penny stocks that are very volatile and would affect our results, we still choose to 
implement this method. Table 5 presents the results after having excluded all companies with a 
market cap of less than USD 500 million. In addition to the value weighting and the equal 
weighting, we also consider a value-weighted version of our portfolio that is controlled for 
liquidity. We perform this analysis, because some of our stocks are small caps or even penny 
stocks and this procedure puts more emphasis on real investability. Moreover, it is not possible or 
at least difficult to invest in some of the companies. Therefore, we exclude all companies whose 
trading volume is less than 20% of the available shares per month. The results of this second test 
are also presented in Table 5.  
(Table 5 about here) 
Table 5 presents alpha estimates for the full period as well as for the bull and the bear 
periods of the equal-weighted and liquidity-adjusted regressions. The table shows that our results 
for the global health-care investments are generally robust with respect to the addressed 
modifications. Like in Table 2 and Table 3, we find an outperformance of the global portfolio in 
the full period as well as in the bull period, whereas we observe no significant alpha estimates in 
the bear period. This result is valid for both the equal-weighted portfolio and the liquidity adjusted 
portfolio. When considering the regional sample, we find no outperformance for both weighing 
methods in the bear period.4 Moving to the bull periods, we observe a totally different picture than 
                                                 
4 We excluded the Australia sample as the number of companies is too low in order to obtain a trustworthy result. 
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that of the bear periods. All portfolios have positive alphas, most of them being statistically 
significant. Especially in Asia, we observe very high alphas for both portfolio formation methods 
with approximately 10 % premium per year. The results of the regional sample also reveal that 
the outperformance is even larger after excluding companies with low turnover on the stock 
exchange. Sample 3 of Table 5 presents the health-care portfolios by sub-industry. We find a 
significant outperformance on the pharmaceutical group in the total period and in the bull period, 
which is statistically significant regardless of the weighting method. The equally-weighted health 
care providers and services portfolio as well as the equipment and supplies portfolio outperform 
in the full period as well as in the bull period and tend towards displaying an outperformance in 
the liquidity-adjusted variant. All other alphas are not statistically significantly different to zero. 
These results prove that our findings of the previous analyses are neither driven by the method we 
apply to compile our portfolio nor by an investment strategy that cannot be applied in practice (as 
the stocks are not investable due to low turnover). In contrast, it shows that the outperformance 
of the health-care industry is really driven by the characteristics of the industry. 
 
5 Concluding Remarks 
 The health-care industry is amongst the largest industries offering many opportunities for 
an investment globally. However, academic literature on this sector is scare. This paper is the first 
to analyze the global health care industry from various perspectives. By analyzing 3,680 
companies from all over the world, we find a statistically significant outperformance of the sector 
on a global basis in a period starting in 2000 and ending in June 2015. In addition, our results 
prove that the companies from the health-care sector have a lower risk level than the market 
benchmark. After splitting the global portfolios into regional portfolios, we observe that the 
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outperformance is driven by companies from the Americas and Asia and, if small companies are 
weighted equally, also from Europe. A second split into sub-industries reveals that the 
outperformance is strongest in pharmaceutical companies. However, if weighted equally, the 
health care equipment & supplies industry also reveals an outperformance. When splitting our 
sample into bull and bear market periods and analyzing the performance separately, we observe 
that the outperformance of the industry is driven by expanding markets and not by bear periods, 
as some might expect. This result is statistically significant on a global, regional and industry 
specific basis. Most financial studies analyze returns only on a USD basis. In addition to this 
standard approach, we analyze the health-care industry in Euro and show that on a risk adjusted 
basis, the results for an investor outside the USD area are different to those of a US investor but, 
nevertheless, the EUR investor can also achieve a significant outperformance. 
   Regarding an explanation for the observed phenomena as well as their possible persistence, we 
revert to demographic-economic argumentation. First, it is well-known that the population is 
growing globally while the share of older people is growing disproportionately faster. This is due 
to the worldwide trend towards a longer life expectancy (see e.g. National Institute on Aging 
(2011)).  Second, the risk of developing most types of chronic diseases (like diabetes, cancer or 
arthritis) increases with age (see e.g. Yashin et al. (2016)).  And third, the medical and economic 
progress in many economies makes it possible and affordable to prolong the lives of those 
suffering from these diseases for many years (see e.g. Bunker (2001)). This mechanism is steadily 
increasing the costs for health care in many countries and, on average, also the cash flows of the 
firms in this sector. These arguments are especially true for the Asian region as the population 
there has been growing enormously and the awareness of health-care provision is increasing there.      
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The general trend towards more elderly people is valid worldwide and also can be prolonged in 
the future, as demographic projections show (National Institute on Aging (2011)). Given these 
considerations, the question may of why it is possible to achieve abnormal returns for such a long 
time still remains relevant. An argument supporting the corresponding finding may be that 
analysts face a hard challenge in forecasting the cash flows of a certain health-care company, 
which may be very risky, even if the development for the whole sector appears to be clear.  
In summary, our results are of interest to investors as they reveal that there are several 
variables that have to be considered when investing in the health care industry. Most important 
are timing, regional focus, sub-industries and the effect of the location of the investor.  
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Figure 1: 100 USD Investment in the health-care portfolio and the market benchmark 
 
This figure illustrates the development of a $100 investment in the value weighted health-care portfolio 
(dashed line) over the sample period from January 2000 through June 2015. For comparison, an investment 
in the market benchmark MSCI World (solid line) is included. 
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Table 1: Summary statistics of the health-care portfolio 
 
 
This table presents the summary statistics, with the total number of 
health care firms, the number of dead firms, and the average return.  
 
 
  
 Figure  Unit  Result 
Firms [#] 3,680 
thereof Dead Firms [#] 160 
Return [%] 0.73 
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Table 2: Financial performance and firm characteristics of the health care industry 
              
  # Alpha Beta SMB HML WML 
Sample 1: Global 
Global 3680 
0.36 0.63 -0.19 0.08 0.08 
(2.20) (13.56) (-1.77) (0.79) (1.74) 
Sample 2: Regions 
Americas 1466 
0.39 0.61 -0.13 0.04 0.06 
(2.04) (8.64) (-1.08) (0.37) (1.08) 
Asia 1267 
0.50 0.58 0.30 -0.06 0.11 
(2.14) (13.12) (2.42) (-0.53) (2.03) 
Australia 148 
0.27 0.78 -0.05 0.20 0.07 
(1.03) (18.14) (-0.35) (1.11) (0.98) 
Europe 702 
0.28 0.63 -0.18 0.06 0.08 
(1.46) (17.34) (-2.49) (0.85) (1.74) 
Sample 3: Industries 
Biotechnology & Medical 
Research 
944 
0.15 0.95 2.28 -1.39 0.58 
(0.30) (7.63) (3.18) (-2.63) (2.41) 
Health care Equipment & 
Supplies 
984 
0.24 0.76 0.54 -0.08 0.14 
(1.24) (13.62) (3.59) (-0.95) (2.42) 
Health care Providers & Services 524 
0.11 0.68 0.38 0.64 0.13 
(0.28) (10.09) (1.96) (3.55) (1.64) 
Pharmaceuticals 1228 
0.45 0.57 -0.50 0.10 0.03 
(2.47) (11.61) (-4.79) (0.89) (0.68) 
              
This table presents alpha estimates and portfolio characteristics based on the factor sensitivities obtained from 
regressing the monthly excess returns of the value weighted health-care portfolio on the explanatory factors of the 
four-factor model. Robust t-statistics derived from Newey and West (1987) standard errors are reported in parentheses. 
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Table 3: Alpha estimates for Bull and Bear periods  
      
  Alpha Bear Alpha Bull 
Sample 1: Global 
Global 
0.07 0.47 
(0.16) (2.65) 
Sample 2: Regions 
Americas 
0.24 0.44 
(0.49) (2.00) 
Asia 
0.00 0.67 
(0.00) (2.55) 
Australia 
-0.53 0.56 
(-0.73) (1.90) 
Europe 
-0.53 0.56 
(-0.73) (1.90) 
Sample 3: Industries 
Biotechnology & Medical Research 
-0.12 0.26 
(-0.09) (0.48) 
Health care Equipment & Supplies 
0.21 0.25 
(0.57) (1.20) 
Health care Providers & Services 
0.27 0.05 
(0.30) (0.13) 
Pharmaceuticals 
0.16 0.55 
(0.36) (2.82) 
      
This table presents alpha estimates for the full period, as well as bull and bear periods 
obtained from regressing the monthly excess returns of the value weighted health-care 
portfolio on the explanatory factors of the four-factor model. Robust t-statistics derived 
from Newey and West (1987) standard errors are reported in parentheses. 
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Table 4: Alpha Estimates for Bull and Bear Periods in Euro 
        
  Alpha Alpha Bear Alpha Bull 
Sample 1: Global 
Global 0.24 -0.11 0.37 
  (1.35) (-0.25) (2.15) 
Sample 2: Regions 
Americas 0.28 0.12 0.33 
  (1.29) (0.23) (1.47) 
Asia 0.48 -0.03 0.64 
  (2.03) (-0.08) (2.46) 
Australia 0.24 0.05 0.80 
  (0.93) (0.07) (2.62) 
Europe 0.14 -0.34 0.31 
  (0.75) (-0.66) (1.84) 
Sample 3: Industries 
Biotechnology & Medical Research 0.60 0.37 0.68 
  (0.9) (0.26) (1.03) 
Health care Equipment & Supplies 0.35 0.33 0.36 
  (1.98) (0.93) (1.74) 
Health care Providers & Services 0.41 0.49 0.38 
  (1.2) (0.52) (1.15) 
Pharmaceuticals 0.19 -0.15 0.32 
  (0.92) (-0.28) (1.56) 
        
This table presents alpha estimates for bull and bear periods obtained from regressing the monthly excess 
returns of the value weighted health-care portfolio on the explanatory factors of the four-factor model. The 
calculations are based on portfolios in the currency Euro. Robust t-statistics derived from Newey and West 
(1987) standard errors are reported in parentheses. 
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Table 5: Alpha estimates for bull and bear periods for equal-weighted and liquidity adjusted portofolios 
 
                
  Equally Weighted   Liquidity 
  Alpha Alpha Bear Alpha Bull   Alpha Alpha Bear Alpha Bull 
Sample 1: Global 
Global 
0.43 0.15 0.53   0.44 0.14 0.56 
(2.17) (0.27) (2.61)   (2.41) (0.30) (2.72) 
Sample 2: Regions 
Americas 0.22 -0.30 0.42   0.37 0.27 0.41 
  (0.83) (-0.37) (1.5)   (1.76) (0.48) (1.71) 
Asia 0.89 -0.16 1.26   0.83 -0.54 1.30 
  (2.51) (-0.29) (2.73)   (2.38) (-0.92) (3.19) 
Australia 0.19 -0.56 0.45         
  (0.66) (-0.73) (1.65)         
Europe 0.66 0.93 0.57   0.27 -0.26 0.45 
  (3.03) (1.53) (3.29)   (1.03) (-0.43) (1.68) 
Sample 3: Industries 
Biotechnology & Medical Research 0.13 0.45 0.01   0.49 0.49 0.49 
  (0.27) (0.35) (0.03)   (1.07) (0.39) (1.02) 
Health care Equipment & Supplies 0.38 0.35 0.39   0.32 0.41 0.29 
  (2.33) (0.8) (2.42)   (1.48) (0.95) (1.24) 
Health care Providers & Services 0.38 0.01 0.52   0.39 0.17 0.47 
  (1.3) (0.01) (1.67)   (0.84) (0.13) (1.39) 
Pharmaceuticals 0.77 0.18 0.98   0.42 -0.13 0.62 
  (3.02) (0.34) (3.30)   (1.70) (-0.20) (2.54) 
                
This table presents alpha estimates for the full period, as well as the bull and bear periods obtained from regressing the monthly excess returns of the health-care 
portfolio on the explanatory factors of the four-factor model. The portfolios are either equally weighted or adjusted for liquidity. Robust t-statistics derived from Newey 
and West (1987) standard errors are reported in parentheses. 
 
